Pfizer's Centers for Therapeutic Innovation (CTI) enable us to partner more closely with academic scientists located at major biotech hubs in the U.S., all in an effort to accelerate the translation of emerging science into new therapies. CTI combines the research expertise of academic experts in disease, targets and patient populations with Pfizer's R&D knowledge, resources and development capabilities. CTI's innovative business model allows academic scientists to share more fully in the value of their science and positions Pfizer to potentially enrich our R&D pipeline with innovative next generation therapeutics.
Our programs in development include potential treatments for autoimmune diseases such as inflammatory bowel disease, lupus, cardiovascular disease, diabetes, cancer, neurological diseases and pain, as well as vaccines for meningococcal B disease in adolescents and for Staphylococcus aureus.
View the latest pipeline on pfizer.com
Pfizer has established three R&D priorities, unfolding over time, to focus on advancing a differentiated pipeline of medicines and vaccines.
Underlying our choices is a focus on increasing differentiation and innovation and improving R&D productivity and return on investment over the long term, while at the same time seeking to ensure we execute effectively on our near-term pipeline priorities. Two years after launching a comprehensive R&D turnaround effort, we are seeing positive indicators, with a robust portfolio grounded in rigorous decision making and an ownership culture.
First and foremost, we are concentrating internal efforts where we believe we can deliver the greatest medical and commercial impact in areas of significant patient need. Over the last year, Pfizer has gained momentum in our late-stage pipeline with key regulatory approvals for important new medicines, including Eliquis (apixaban) for stroke prevention in nonvalvular atrial fibrillation, Xeljanz (tofacitinib), a first-in-class JAK inhibitor for moderate-to-severe rheumatoid arthritis, and the oncology compounds Inlyta (axitinib) and Bosulif (bosutinib).
Pfizer is advancing a solid late-stage pipeline, including a number of Phase III programs in areas of critical patient need, such as:
Pfizer is focused on innovative capabilities that can position the company for long term competitive advantage. This includes the significant expansion of our vaccine development program, which now includes investigational first-in-class therapeutic and prophylactic vaccines targeting smoking cessation and deadly hospital-acquired infections. It also includes a leading platform in next-generation antibody drug conjugates (ADCs), which are targeted treatments for cancer that include an antibody and cancer cytotoxic in one medicine. Pfizer has cutting-edge small and large molecule technology capabilities that position us to develop fit-for-purpose optimized medicines for patient needs.
In addition to scientific capabilities Pfizer is at the forefront of innovating novel open-innovation models such as the CTIs, where Pfizer scientists work in real time with academic scientists to expedite the translation of science into medicine.
Key early-to-mid-stage clinical programs that reflect our new capabilities include:
We are moving toward a much more networked R&D model—shaping how biopharmaceutical innovation will be done. The R&D ecosystem of the future will draw on the total capabilities in the biomedical community, reducing silos and increasing productivity.
Critical to this new ecosystem is optimizing the promise of Precision Medicine, an approach to discovering, developing and commercializing medicines that we believe will deliver superior clinical outcomes in complex diseases, identify patient populations that are most likely to respond to our medicines and expedite the timelines for drug development.
